Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157638 | 0.84 | HSD11B1 (0.58) | HSD11B1EPHX1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL5157965 | 0.82 | HSD11B1 (0.61) | HSD11B1EPHX1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL6507281 | 0.81 | HSD11B1 (0.46) | HSD11B1CYP2C9EPHX1NR1H2HSD17B10 | |
| SCHEMBL5157458 | 0.81 | HSD11B1 (0.46) | HSD11B1CYP2C9EPHX1NR1H2HSD17B10 | |
| SCHEMBL6510853 | 0.79 | FEN1 (0.43) | EPHX1NR1H2HSD17B10 | |
| SCHEMBL5157466 | 0.76 | HSD11B1 (0.58) | HSD11B1CYP2C9EPHX1HSD17B10L3MBTL1 | |
| SCHEMBL5158011 | 0.74 | HSD11B1 (0.51) | HSD11B1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL6504698 | 0.74 | HSD11B1 (0.62) | HSD11B1EPHX1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL5160276 | 0.74 | HSD11B1 (0.62) | HSD11B1EPHX1HSD17B10L3MBTL1EPHX2 | |
| SCHEMBL6502476 | 0.72 | HSD11B1 (0.57) | HSD11B1EPHX1HSD17B10L3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885CYP2C9 550/4885EPHX1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.